|Bid||11.44 x 1400|
|Ask||11.46 x 800|
|Day's range||11.22 - 11.97|
|52-week range||5.75 - 18.48|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.
Bionano Genomics, BioCryst Pharmaceuticals, and NRx Pharmaceuticals all have the potential to make their early shareholders rich.
Participating with me today are CEO Jon Stonehouse; CFO Anthony Doyle; Chief Commercial Officer Charlie Gayer; Chief Medical Officer Dr. Three quarters of the way into 2021, and this has been an amazing year of execution for our company.